Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 30, Supplement - Infectious Diseases and Carceral Health

SUPPLEMENT ISSUE
Policy

Medicaid Inmate Exclusion Policy and Infectious Diseases Care for Justice-Involved Populations

Author affiliations: Tufts University School of Medicine, Boston, Massachusetts, USA (A.G. Wurcel); Massachusetts Sheriffs’ Association, Boston (A.G. Wurcel, N. Cocchi, P.J. Koutoujian); University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA (K. London); University of California San Diego, La Jolla, California, USA (E.L. Crable); Hampden County Sheriff’s Office, Springfield, Massachusetts, USA (N. Cocchi); Middlesex County Sheriff’s Office, Woburn, Massachusetts, USA (P.J. Koutoujian); Hennepin Healthcare Research Institute, Minneapolis, Minnesota, USA (T.N.A. Winkelman)

Cite This Article

Abstract

The Medicaid Inmate Exclusion Policy (MIEP) prohibits using federal funds for ambulatory care services and medications (including for infectious diseases) for incarcerated persons. More than one quarter of states, including California and Massachusetts, have asked the federal government for authority to waive the MIEP. To improve health outcomes and continuation of care, those states seek to cover transitional care services provided to persons in the period before release from incarceration. The Massachusetts Sheriffs’ Association, Massachusetts Department of Correction, Executive Office of Health and Human Services, and University of Massachusetts Chan Medical School have collaborated to improve infectious disease healthcare service provision before and after release from incarceration. They seek to provide stakeholders working at the intersection of criminal justice and healthcare with tools to advance Medicaid policy and improve treatment and prevention of infectious diseases for persons in jails and prisons by removing MIEP barriers through Section 1115 waivers.

Rates of illness and death from infections among justice-involved populations are high. Infections disparately affect persons incarcerated in correctional settings because of the syndemic relationship of infectious diseases, racism, and incarceration (14). In the early 1980s, high rates of HIV infection, hepatitis, and tuberculosis in correctional settings drew attention to missed opportunities to offer infectious disease testing and treatment (5,6). Correctional healthcare accreditation organizations, correctional administrators, public health officials, and clinicians have collectively advanced infectious disease care in correctional settings through investment into tuberculosis and HIV testing as well as HIV treatment and postrelease linkage programs (7,8). However, gaps persist, especially during transition from incarceration to community (9,10). Minoritized persons (including those who are Black, Hispanic, Indigenous, or sexually minoritized) are disproportionately incarcerated and particularly affected by lack of infectious disease treatment and prevention services in correctional settings and at re-entry into the community (1113).

Resources allocated for infectious disease treatment and prevention in correctional settings are well documented as inadequate (14). Policy and financing reforms are needed to improve infectious disease prevention and treatment among justice-involved populations. The Medicaid Inmate Exclusion Policy (MIEP) prohibits federal Medicaid reimbursement for healthcare services delivered to any incarcerated person, except for hospital stays of >24 hours. Many states have applied to the federal government to waive MIEP through a Section 1115 Medicaid demonstration (hereafter referred to as the 1115 MIEP waiver) (15). We outline the history of MIEP, reflect on facilitators of and barriers to infectious disease care in correctional settings, and use the cross-disciplinary collaboration supporting application for an MIEP waiver in Massachusetts to highlight how infectious disease care paradigms could be positively affected by an 1115 MIEP waiver.

Creation and Restructuring of the MIEP

In 1965, the Social Security Act created Medicaid as an insurance program to support access to healthcare for persons with limited income. The Social Security Act established the Inmate and the Institutions for Mental Disease exclusion policies to prohibit Medicaid reimbursement for services delivered in institutions, but it also allowed states to test new ways of delivering care through application for an 1115 MIEP waiver. In 1965, healthcare services available to persons living in the community were not routinely offered to incarcerated populations (16). In 1976, the United States Supreme Court ruled in Estelle v Gamble that correctional settings that failed to provide incarcerated persons with adequate medical care commensurate with the community-standard was a violation of the Eighth Amendment of the US Constitution. Although access to healthcare in correctional settings has vastly improved since then, wide variability remains (17,18).

Before the Affordable Care Act Medicaid expansion in 2014 (19), many persons released from incarceration did not meet their states’ Medicaid eligibility requirements, which often did not cover low-income adults without children. In states that expanded Medicaid under the Affordable Care Act, most persons became eligible for Medicaid at the time of release from incarceration; however, MIEP continued to prevent activation of Medicaid coverage during incarceration. In 1997, the Centers for Medicare & Medicaid Services (CMS) modified the scope of the MIEP by reinstating Medicaid coverage for incarcerated persons who are hospitalized >24 hours but continued to prohibit Medicaid coverage for outpatient services during incarceration (20).

Barriers to Care Created by the MIEP

Barriers to Infectious Disease Care during Incarceration

In 2011, an estimated one fifth of state department of corrections’ operational budgets was spent on healthcare (21). Even so, correctional budgets have been insufficient to meet the need, and the MIEP prevents Medicaid from filling this gap. For example, offering hepatitis C treatment to everyone who needs it has been challenging because of the cost (>$80,000 per treatment), a recommended treatment period of 8–12 weeks, and high rates of hepatitis C virus infection in jails and prisons (22,23). Other challenges for correctional healthcare budgets are paying for long-acting injectable medications that treat or prevent HIV infection and adopting substance use disorder treatments in jails and prisons (24,25). Many jails and prisons in the United States now offer medications for treatment of opioid use disorder and substance use disorder to prevent the risk for medical complications (e.g., withdrawal and death). However, medication continuity for opioid use disorder and many infectious disease conditions during and after incarceration remains poor (26).

Barriers to Continuity of Care during Transitions from Correctional to Community Healthcare

Because Medicaid coverage is suspended or terminated during incarceration, it needs to be reactivated for persons to receive care when they return to the community. Most persons incarcerated in the United States spend short periods (<30 days) in jail (27) and often cycle multiple times from jail to community, further fragmenting needed care. People leaving jail and prison face barriers getting Medicaid reactivated, making appointments, and getting medications (28,29). Another barrier, with its own set of challenges, is data sharing between correctional and community healthcare systems (30). Virus eradication (hepatitis C virus) and virus suppression (HIV) are needed to end the hepatitis C and HIV infection epidemics, yet persons who leave jail and prisons with those infections often encounter administrative, geographic, and financial hurdles blocking access to treatment, further complicated by competing priorities of housing, food insecurity, and unemployment (3135). Persons with untreated HIV infection (36), viral hepatitis (37), and substance use disorder (38) are particularly at risk for disjointed care when transitioning to the community.

Cross-Disciplinary Collaboration in Massachusetts to Promote Healthcare Access and Waive MIEP

As of January 2024, at least one quarter of states, including Massachusetts, had applied for an 1115 MIEP waiver. In 2023, CMS granted 1115 MIEP waiver requests to California and Washington to cover transitional care services provided to persons in the 90 days before their release from incarceration (39), and CMS issued guidance to help states understand what provisions might be waived (40). In December 2021, Massachusetts submitted an 1115 MIEP waiver request with input from many collaborators, including but not limited to the Massachusetts Sheriffs’ Association and Department of Correction. As outlined in the waiver application, the major goals for Massachusetts are to improve prerelease and postrelease care management and connection to healthcare services, to improve healthcare outcomes, and to decrease outcome disparities (41,42). Incarcerated persons who meet Massachusetts Medicaid income eligibility criteria would be able to receive Medicaid covered services during a prerelease period. To ensure that all persons incarcerated within a facility have equal access to healthcare services, correctional budgets would need to support provision of Medicaid-covered services for persons who do not meet Medicaid eligibility requirements. Massachusetts originally requested coverage during a prerelease period of 30 days (43); the recent CMS guidance allowed a prerelease period of up to 90 days (40), and Massachusetts resubmitted its waiver request on October 16, 2023, proposing coverage 90 days before release for all incarcerated persons (43).

Operationalization of an 1115 MIEP Waiver to Improve Infectious Disease Care

An 1115 MIEP waiver would provide several opportunities for improving infectious disease care. High-cost, evidence-based medications (e.g., for treatment for hepatitis C and preexposure prophylaxis for HIV) could be initiated before release and supported by robust linkage to care programs after release. Medications and treatment for substance use disorder could be augmented, reimbursed, and continued seamlessly in the community, enhancing opportunities for successful re-entry. Intensified support for care coordination and for linkage to care at the time of re-entry has also been proposed in the newest application—a strategy that has been shown to increase continuation of care and improve infectious disease outcomes (4446). Care coordination staff embedded within the jail or prison would assist with completion of health insurance paperwork, scheduling of clinician appointments, and other tasks at re-entry. Data sharing between the correctional health system and the community health system would be improved. An 1115 MIEP waiver could change the experience of a person with an infectious disease or substance use disorder transitioning from correctional to community healthcare (Table).

The 1115 MIEP waiver requested by Massachusetts would support a warm handoff, either through in-person or telehealth meetings, in which the clinician who will be treating the person in the community can meet with the jail or prison clinician. Medicaid enrollment during incarceration would enable providers to schedule appointments for persons soon after their expected release date; in some cases, the community provider might meet with the patient in person or via telehealth visit before release (47). The process of such handoffs is intended to reduce apprehension about stigmatizing experiences in the community and to improve engagement in postrelease care. The approach used by the Transitions Clinic Network, with 48 clinics across the country, serves as a model for hiring, training, and supporting a workforce dedicated to health at the time of re-entry (48,49).

As states implement MIEP-related policy changes, they should develop monitoring systems to help identify potential delays in healthcare access that may occur during incarceration or at the time of re-entry into the community. Moreover, states should establish accountability processes to ensure that correctional settings do not delay healthcare delivery until 90 days before release, when Medicaid could reimburse services rendered. For example, persons with liver disease from hepatitis C should be prioritized for treatment as soon as possible. Collaborative systems of care and open communication between clinicians, correctional administrators, and public health agencies should ensure that appropriate healthcare is delivered throughout incarceration and at re-entry into the community.

Conclusions

Building on 1115 MIEP waiver–associated successes and lessons in California, Washington, and, eventually, Massachusetts, state Medicaid agencies can request to waive the federal MIEP to positively affect eligible justice-involved persons and the broader public. Repealing MIEP at the federal level would eliminate the need for states to apply for MIEP waivers. The growing number of 1115 MIEP waiver applications signals the strength of cross-sector partnerships among public health, policy, healthcare, and correctional leaders that can be leveraged for more robust legislative change to improve continuity of healthcare for incarcerated persons.

Dr. Wurcel is an infectious diseases clinician working in jails and at Tufts Medical Center and is also a health services researcher. She is a consultant to the Massachusetts Sheriffs’ Association.

Top

References

  1. Macalino  GE, Vlahov  D, Sanford-Colby  S, Patel  S, Sabin  K, Salas  C, et al. Prevalence and incidence of HIV, hepatitis B virus, and hepatitis C virus infections among males in Rhode Island prisons. Am J Public Health. 2004;94:121823. DOIPubMedGoogle Scholar
  2. LeMasters  K, Brinkley-Rubinstein  L, Maner  M, Peterson  M, Nowotny  K, Bailey  Z. Carceral epidemiology: mass incarceration and structural racism during the COVID-19 pandemic. Lancet Public Health. 2022;7:e28790. DOIPubMedGoogle Scholar
  3. Asabor  EN, Vermund  SH. Confronting structural racism in the prevention and control of tuberculosis in the United States. Clin Infect Dis. 2021;73:e35315. DOIPubMedGoogle Scholar
  4. Spaulding  AC, Rabeeah  Z, Del Mar González-Montalvo  M, Akiyama  MJ, Baker  BJ, Bauer  HM, et al.; Rollins Investigational Team on STIs in Corrections. Prevalence and management of sexually transmitted infections in correctional settings: a systematic review. Clin Infect Dis. 2022;74(Suppl_2):S193217. DOIPubMedGoogle Scholar
  5. Snider  DE Jr, Hutton  MD. Tuberculosis in correctional institutions. JAMA. 1989;261:4367. DOIPubMedGoogle Scholar
  6. Baillargeon  J, Black  SA, Pulvino  J, Dunn  K. The disease profile of Texas prison inmates. Ann Epidemiol. 2000;10:7480. DOIPubMedGoogle Scholar
  7. Glaser  JB, Greifinger  RB. Correctional health care: a public health opportunity. Ann Intern Med. 1993;118:13945. DOIPubMedGoogle Scholar
  8. Arriola  KR, Kennedy  SS, Coltharp  JC, Braithwaite  RL, Hammett  TM, Tinsley  MJ. Development and implementation of the cross-site evaluation of the CDC/HRSA corrections demonstration project. AIDS Educ Prev. 2002;14(Suppl A):10718. DOIPubMedGoogle Scholar
  9. Olson  M, Shlafer  RJ, Bodurtha  P, Watkins  J, Hougham  C, Winkelman  TNA. Health profiles and racial disparities among individuals on probation in Hennepin County, Minnesota, 2016: a cross-sectional study. BMJ Open. 2021;11:e047930. DOIPubMedGoogle Scholar
  10. Maruschak  L, Bronson  J, Alper  M. Medical problems reported by prisoners, survey of prison inmates, 2016. Washington (DC): US Department of Justice, Bureau of Justice Statistics; 2021.
  11. Hochstatter  KR, Akhtar  WZ, El-Bassel  N, Westergaard  RP, Burns  ME. Racial disparities in use of non-emergency outpatient care by Medicaid-eligible adults after release from prison: Wisconsin, 2015-2017. J Subst Abuse Treat. 2021;126:108484. DOIPubMedGoogle Scholar
  12. Sprague  C, Scanlon  ML, Pantalone  DW. Qualitative research methods to advance research on health inequities among previously incarcerated women living with HIV in Alabama. Health Educ Behav. 2017;44:71627. DOIPubMedGoogle Scholar
  13. Brewer  R, Ramani  SL, Khanna  A, Fujimoto  K, Schneider  JA, Hotton  A, et al. A systematic review up to 2018 of HIV and associated factors among criminal justice-involved (CJI) black sexual and gender minority populations in the United States (US). J Racial Ethn Health Disparities. 2022;9:1357402. DOIPubMedGoogle Scholar
  14. Pew Charitable Trusts. Prison health care costs and quality [cited 2023 May 8]. https://www.pewtrusts.org/en/research-and-analysis/reports/2017/10/prison-health-care
  15. Social Security Administration. Compilation of the Social Security laws [cited 2023 May 8]. https://www.ssa.gov/OP_Home/ssact/title11/1115.htm
  16. Goldsmith  SB. The status of prison health care. A review of the literature. Public Health Rep. 1974;89:56975.PubMedGoogle Scholar
  17. Steadman  HJ, Holohean  EJ Jr, Dvoskin  J. Estimating mental health needs and service utilization among prison inmates. Bull Am Acad Psychiatry Law. 1991;19:297307.PubMedGoogle Scholar
  18. Lichtenstein  RL, Rykwalder  A. Licensed physicians who work in prisons: a profile. Public Health Rep. 1983;98:58996.PubMedGoogle Scholar
  19. Howell  BA, Hawks  L, Wang  EA, Winkelman  TNA. Evaluation of changes in US health insurance coverage for individuals with criminal legal involvement in Medicaid expansion and nonexpansion states, 2010 to 2017. JAMA Health Forum. 2022;3:e220493. DOIPubMedGoogle Scholar
  20. Streimer  RA. Clarification of Medicaid coverage policy for inmates of a public institution. Washington (DC): US Department of Health and Human Services; 1997.
  21. Pew Charitable Trusts. State prison healthcare spending [cited 2023 May 8] https://www.pewtrusts.org/en/research-and-analysis/reports/2014/07/08/state-prison-health-care-spending
  22. Nguyen  JT, Rich  JD, Brockmann  BW, Vohr  F, Spaulding  A, Montague  BT. A budget impact analysis of newly available hepatitis C therapeutics and the financial burden on a state correctional system. J Urban Health. 2015;92:63549. DOIPubMedGoogle Scholar
  23. Wurcel  AG, Reyes  J, Zubiago  J, Koutoujian  PJ, Burke  D, Knox  TA, et al. “I’m not gonna be able to do anything about it, then what’s the point?”: A broad group of stakeholders identify barriers and facilitators to HCV testing in a Massachusetts jail. PLoS One. 2021;16:e0250901. DOIPubMedGoogle Scholar
  24. Ryan  DA, Montoya  ID, Koutoujian  PJ, Siddiqi  K, Hayes  E, Jeng  PJ, et al. Budget impact tool for the incorporation of medications for opioid use disorder into jail/prison facilities. J Subst Use Addict Treat. 2023;146:208943. DOIPubMedGoogle Scholar
  25. Bounthavong  M. Is providing medications for opioid use disorder to incarcerated individuals a cost-effective strategy? JAMA Netw Open. 2023;6:e237001. DOIPubMedGoogle Scholar
  26. Howell  BA, Hawks  LC, Balasuriya  L, Chang  VW, Wang  EA, Winkelman  TNA. Health insurance and mental health treatment use among adults with criminal legal involvement after Medicaid expansion. Psychiatr Serv. 2023;74:101926. DOIPubMedGoogle Scholar
  27. Zeng  Z, Minton  TD. Jail inmates in 2016 [cited 2032 May 1]. https://bjs.ojp.gov/content/pub/pdf/ji19.pdf
  28. Binswanger  IA, Stern  MF, Deyo  RA, Heagerty  PJ, Cheadle  A, Elmore  JG, et al. Release from prison—a high risk of death for former inmates. N Engl J Med. 2007;356:15765. DOIPubMedGoogle Scholar
  29. Hyde  J, Byrne  T, Petrakis  BA, Yakovchenko  V, Kim  B, Fincke  G, et al. Enhancing community integration after incarceration: findings from a prospective study of an intensive peer support intervention for veterans with an historical comparison group. Health Justice. 2022;10:33. DOIPubMedGoogle Scholar
  30. Glowalla  G, Subbian  V. Data sharing between jail and community health systems: missing links and lessons for re-entry success. Stud Health Technol Inform. 2022;290:4751. DOIPubMedGoogle Scholar
  31. Howell  BA, Hawks  L, Wang  EA, Winkelman  TNA. Evaluation of changes in US health insurance coverage for individuals with criminal legal involvement in Medicaid expansion and nonexpansion states, 2010 to 2017. JAMA Health Forum. 2022;3:e220493. DOIPubMedGoogle Scholar
  32. Hoffman  KA, Thompson  E, Gaeta Gazzola  M, Oberleitner  LMS, Eller  A, Madden  LM, et al. “Just fighting for my life to stay alive”: a qualitative investigation of barriers and facilitators to community re-entry among people with opioid use disorder and incarceration histories. Addict Sci Clin Pract. 2023;18:16. DOIPubMedGoogle Scholar
  33. Knapp  CD, Howell  BA, Wang  EA, Shlafer  RJ, Hardeman  RR, Winkelman  TNA. Health insurance gains after implementation of the Affordable Care Act among individuals recently on probation: USA, 2008–2016. J Gen Intern Med. 2019;34:10868. DOIPubMedGoogle Scholar
  34. Khatri  UG, Howell  BA, Winkelman  TNA. Medicaid expansion increased medications for opioid use disorder among adults referred by criminal justice agencies. Health Aff (Millwood). 2021;40:56270. DOIPubMedGoogle Scholar
  35. Gillot  M, Gant  Z, Hu  X, Satcher Johnson  A. Linkage to HIV medical care and social determinants of health among adults with diagnosed HIV infection in 41 states and the District of Columbia, 2017. Public Health Rep. 2022;137:888900. DOIPubMedGoogle Scholar
  36. Loeliger  KB, Altice  FL, Ciarleglio  MM, Rich  KM, Chandra  DK, Gallagher  C, et al. All-cause mortality among people with HIV released from an integrated system of jails and prisons in Connecticut, USA, 2007-14: a retrospective observational cohort study. Lancet HIV. 2018;5:e61728. DOIPubMedGoogle Scholar
  37. Binswanger  IA, Blatchford  PJ, Forsyth  SJ, Stern  MF, Kinner  SA. Epidemiology of infectious disease-related death after release from prison, Washington State, United States, and Queensland, Australia: a cohort study. Public Health Rep. 2016;131:57482. DOIPubMedGoogle Scholar
  38. Merrall  EL, Kariminia  A, Binswanger  IA, Hobbs  MS, Farrell  M, Marsden  J, et al. Meta-analysis of drug-related deaths soon after release from prison. Addiction. 2010;105:154554. DOIPubMedGoogle Scholar
  39. Enos  G. California earns groundbreaking waiver for Medicaid pre‐release services. Ment Health Wkly. 2023;33:17. DOIGoogle Scholar
  40. US Department of Health and Human Services. Opportunities to test transition-related strategies to support community reentry and improve care transitions for individuals who are incarcerated. 2023 [cited 2023 May 1]. https://www.medicaid.gov/sites/default/files/2023-12/smd23003.pdf
  41. Mass.gov. Section 1115 demonstration project extension request [cited 2023 May 1]. https://www.mass.gov/info-details/1115-masshealth-demonstration-waiver-extension-request
  42. Koutoujian  P. Medicaid should cover the incarcerated [cited 2023 May 1] https://commonwealthbeacon.org/criminal-justice/medicaid-should-cover-the-incarcerated/
  43. Mass.gov. 1115 MassHealth Demonstration (“Waiver”) [cited 2023 May 1]. https://www.mass.gov/info-details/1115-masshealth-demonstration-waiver
  44. Draine  J, Ahuja  D, Altice  FL, Arriola  KJ, Avery  AK, Beckwith  CG, et al. Strategies to enhance linkages between care for HIV/AIDS in jail and community settings. AIDS Care. 2011;23:36677. DOIPubMedGoogle Scholar
  45. Taweh  N, Schlossberg  E, Frank  C, Nijhawan  A, Kuo  I, Knight  K, et al. Linking criminal justice-involved individuals to HIV, Hepatitis C, and opioid use disorder prevention and treatment services upon release to the community: Progress, gaps, and future directions. Int J Drug Policy. 2021;96:103283. DOIPubMedGoogle Scholar
  46. Westergaard  RP, Spaulding  AC, Flanigan  TP. HIV among persons incarcerated in the USA: a review of evolving concepts in testing, treatment, and linkage to community care. Curr Opin Infect Dis. 2013;26:106. DOIPubMedGoogle Scholar
  47. Baker  O, Wellington  C, Price  CR, Tracey  D, Powell  L, Loffredo  S, et al. Experience delivering an integrated service model to people with criminal justice system involvement and housing insecurity. BMC Public Health. 2023;23:222. DOIPubMedGoogle Scholar
  48. Wang  EA, Hong  CS, Samuels  L, Shavit  S, Sanders  R, Kushel  M. Transitions clinic: creating a community-based model of health care for recently released California prisoners. Public Health Rep. 2010;125:1717. DOIPubMedGoogle Scholar
  49. Harvey  TD, Busch  SH, Lin  HJ, Aminawung  JA, Puglisi  L, Shavit  S, et al. Cost savings of a primary care program for individuals recently released from prison: a propensity-matched study. BMC Health Serv Res. 2022;22:585. DOIPubMedGoogle Scholar

Top

Table

Top

Cite This Article

DOI: 10.3201/eid3013.230742

1Current affiliation: Independent consultant.

Table of Contents – Volume 30, Supplement—March 2024

EID Search Options
presentation_01 Advanced Article Search – Search articles by author and/or keyword.
presentation_01 Articles by Country Search – Search articles by the topic country.
presentation_01 Article Type Search – Search articles by article type and issue.

Top

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Alysse G. Wurcel, Tufts Medical Center, Infectious Diseases, 800 Washington St, Boston, MA 02118, USA

Send To

10000 character(s) remaining.

Top

Page created: March 14, 2024
Page updated: March 31, 2024
Page reviewed: March 31, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external